Automatic Website Traffic RSS

CTLA-4: a key protein in autoimmunity

Interestingly, CTLA-4 knockout mice and mice that lack expression of CTLA-4 just in T REG develop fatal, early-onset lymphoproliferative disease. 1,4 In addition, expression and signaling of CTLA ... read more

Mobilizing CD4+ T cells and microglia against glioblastoma

Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ... read more

EMulate’s radiofrequency device proves effective in GBM mouse models

Mice treated with the device exhibited significantly reduced tumour sizes when compared to the untreated cohort. read more

Correlation between plasma levels of soluble immune checkpoint factors and exhaustion of antitumor immunity. (IMAGE)

The concentration of soluble PD-L1m PD-1, CTLA4 in plasma were highly correlated with the expression of genes associated with exhaustion in the peripheral CD8 + T cells. R values were indicated by ... read more

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. read more

ICIs “Should Be Avoided” During Pregnancy

Immune checkpoint inhibitor therapy during pregnancy “should be avoided when possible,” according to researchers. read more

Immune Checkpoint Inhibitors Not Linked to Increased Pregnancy Risks: JAMA

Researchers have found in a new study that exposure to immune checkpoint inhibitors (ICIs) during pregnancy did not demonstrate an increased risk of specific adverse outcomes overall among ... read more

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ... read more

Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update

SalubrisBio also provided progress updates for JK07, the first investigational antibody fusion protein for heart failure, JK08, the first investigational IL15-CTLA4 antibody fusion for solid tumors ... read more

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Merck MRK will report first-quarter 2024 results on Apr 25, before market open. In the last reported quarter, the company delivered an earnings surprise of 133.3%. Factors to Consider The Zacks ... read more

Immunotherapy During Pregnancy Just as Safe as Other Cancer Drugs

However, of note, preterm birth was significantly over-reported among women treated with a combination of anti-PD-1 and anti-CTLA-4 therapies compared with other anticancer drugs (80% vs 23% ... read more